- Home
- CROX vs APGE Comparison
CROX vs APGE Comparison
Compare CROX & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CROX | APGE |
|---|---|---|
| Founded | 1999 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.7B |
| IPO Year | 2006 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CROX | APGE |
|---|---|---|
| Price | $83.35 | $81.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $96.75 | ★ $101.89 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 02-12-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.26 | N/A |
| Revenue | ★ $4,072,780,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.17 | ★ N/A |
| Revenue Growth | ★ 0.01 | N/A |
| 52 Week Low | $73.21 | $26.20 |
| 52 Week High | $122.84 | $80.99 |
Technical Indicators
Market Signals| Indicator | CROX | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 70.20 |
| Support Level | $83.95 | $75.02 |
| Resistance Level | $88.25 | $80.24 |
| Average True Range (ATR) | 3.25 | 3.51 |
| MACD | -0.62 | -0.16 |
| Stochastic Oscillator | 6.73 | 76.25 |
Price Performance
Historical ComparisonAbout CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company are the United States and other Countries.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.